Jun 2026 (Q2 FY26) — Aug 5, 2026
Biote Q2 FY26 — Recall Headwinds Persist, Strategic Initiatives Underway for H2 Growth
Read the full callBiote (BTMD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Biote earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 44.2 | −9.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -7.9 | −30.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -6.6 | −306.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$1.08 −0.92% · −$0.01
Performance −62.0% 1Y
1Y: $2.84 on 17 Oct 2025 → $1.08. High $3.19 (22 Oct 2025), low $1.04 (13 Oct 2026).
- Previous close
- $1.09
- 52-week range
- $1.04 – $3.19
- One year
- −63.14%
Overview
- Symbol
- BTMD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Biote earnings calls (BTMD)
Financials
What the filings say
Net profit, year on year: −306% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 50 | 49 | 49 | 48 | 46 | 45 | 44 |
| Operating profit | 12 | 3 | 10 | 11 | 8 | 7 | 3 | -4 |
| Operating margin | 23.7% | 5.5% | 19.8% | 22.0% | 17.2% | 14.7% | 7.0% | −7.9% |
| Other income | 4 | -4 | 8 | -5 | 0 | -1 | 0 | -4 |
| Profit before tax | 16 | -1 | 17 | 6 | 8 | 6 | 3 | -7 |
| Tax rate | 20.2% | 385.5% | 9.3% | 35.4% | −9.1% | 53.3% | 19.8% | −4.2% |
| Net profit | 11 | 4 | 14 | 3 | 8 | 2 | 2 | -7 |
| EPS ($ per share) | 0.34 | — | 0.44 | 0.10 | 0.26 | — | 0.07 | -0.23 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Reserves | 4 | -44 | -29 | -100 | -50 |
| Total liabilities | 50 | 170 | 192 | 225 | 158 |
| Fixed assets | 2 | 2 | 1 | 7 | 11 |
| Total assets | 54 | 112 | 155 | 122 | 108 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | 34 | -9 | 27 | 45 | 35 |
| Cash from investing | -4 | -2 | -3 | -19 | -7 |
| Cash from financing | -20 | 63 | -14 | -76 | -44 |
| Net cash flow | 10 | 52 | 10 | -50 | -15 |
| Capital expenditure | -1 | -0 | -0 | -6 | -5 |
| Free cash flow | 32 | -9 | 27 | 39 | 30 |
Insider filings
3 filings between May 12, 2026 and Aug 11, 2026.
Open market
decisions to buy or sellPurchases
$202.2K
2 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Beer Marc D | $202.2K | — | Aug 11, 2026 |
Latest filings (26)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Beer Marc D Executive Chairman | Purchase | 16,000 | $24.8K |
| Aug 10, 2026 | Beer Marc D Executive Chairman | Purchase | 115,950 | $177.4K |
| May 12, 2026 | MORRIS DEBRA L Director | Option exercise | 21,407 | — |
| May 13, 2025 | MORRIS DEBRA L Director | Option exercise | 11,045 | — |
| May 13, 2025 | Jacoby Dana Lynn Director | Option exercise | 12,994 | — |
| May 7, 2025 | Guines LLC 10% owner | Purchase | 11,677 | $39.1K |
| May 6, 2025 | Guines LLC 10% owner | Purchase | 436,037 | $1.42M |
| Apr 30, 2025 | Guines LLC 10% owner | Purchase | 1,933 | $6.4K |
| Apr 21, 2025 | Guines LLC 10% owner | Purchase | 8,801 | $28.8K |
| Apr 17, 2025 | Guines LLC 10% owner | Purchase | 6,874 | $22.6K |
| Apr 16, 2025 | Guines LLC 10% owner | Purchase | 1,000 | $3.3K |
| Apr 9, 2025 | Guines LLC 10% owner | Purchase | 13,532 | $43.4K |
| Apr 8, 2025 | Guines LLC 10% owner | Purchase | 34,907 | $112.0K |
| Apr 7, 2025 | Guines LLC 10% owner | Purchase | 43,378 | $136.7K |
| Apr 4, 2025 | Guines LLC 10% owner | Purchase | 23,741 | $77.0K |
| Apr 3, 2025 | Guines LLC 10% owner | Purchase | 7,321 | $23.7K |
| Mar 31, 2025 | Guines LLC 10% owner | Purchase | 106,000 | $351.9K |
| Mar 17, 2025 | Guines LLC 10% owner | Purchase | 100 | $374 |
| Mar 17, 2025 | HEYER ANDREW R Director | Purchase | 50,000 | $197.4K |
| Mar 17, 2025 | HEYER ANDREW R Director | Purchase | 25,000 | $98.7K |
| Mar 17, 2025 | Cone Stephen Mark Director | Purchase | 38,104 | $147.8K |
| Mar 17, 2025 | Christensen Bret Chief Executive Officer | Purchase | 37,595 | $145.5K |
| Mar 17, 2025 | Beer Marc D Director | Purchase | 107,794 | $417.2K |
| Mar 14, 2025 | Guines LLC 10% owner | Purchase | 106,509 | $372.3K |
| Mar 13, 2025 | Guines LLC 10% owner | Purchase | 750,000 | $2.41M |
| Sep 9, 2024 | Peterson Robert Charles Chief Financial Officer | Sale | 32,874 | $203.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for biote Corp.
Free account. Everything above stays public.
Write why you follow biote Corp. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading